Compare CSTM & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | LQDA |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | France | United States |
| Employees | 11500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2012 | 2020 |
| Metric | CSTM | LQDA |
|---|---|---|
| Price | $30.10 | $37.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $30.75 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.1M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 405.26 | 51.81 |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $8,449,000,000.00 | $158,320,000.00 |
| Revenue This Year | $21.46 | $278.87 |
| Revenue Next Year | $0.50 | $57.13 |
| P/E Ratio | $16.08 | ★ N/A |
| Revenue Growth | 15.19 | ★ 1031.18 |
| 52 Week Low | $9.04 | $11.85 |
| 52 Week High | $31.20 | $46.67 |
| Indicator | CSTM | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 47.66 |
| Support Level | $13.79 | $31.75 |
| Resistance Level | $31.20 | $39.19 |
| Average True Range (ATR) | 1.22 | 1.97 |
| MACD | 0.08 | -0.28 |
| Stochastic Oscillator | 69.69 | 19.84 |
Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.